Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 8/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 3/20 | 0.31 |
| ▸ | NOS2 | P35228 | 3/20 | 0.31 |
| ▸ | MAOB | P27338 | 3/20 | 0.31 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5421579 | 0.93 | GPBAR1 (0.36) | GPBAR1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5419735 | 0.85 | NOS1 (0.40) | ROCK2ROCK1GPBAR1OPRM1OPRD1 | |
| SCHEMBL5415719 | 0.83 | ROCK2 (0.36) | ROCK2ROCK1GPBAR1OPRM1OPRD1 | |
| SCHEMBL5596537 | 0.82 | OPRM1 (0.33) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5596659 | 0.81 | ROCK2 (0.36) | ROCK2ROCK1GPBAR1OPRM1OPRD1 | |
| SCHEMBL5596842 | 0.81 | GPBAR1 (0.38) | GPBAR1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5417474 | 0.81 | ROCK2 (0.35) | ROCK2ROCK1GPBAR1OPRM1OPRD1 | |
| SCHEMBL5596599 | 0.81 | GPBAR1 (0.36) | ROCK2ROCK1GPBAR1OPRM1OPRD1 | |
| SCHEMBL5410280 | 0.81 | ROCK2 (0.36) | ROCK2ROCK1GPBAR1OPRM1OPRD1 | |
| SCHEMBL5596785 | 0.81 | ROCK2 (0.38) | ROCK2ROCK1GPBAR1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | ROCK2 255/4885ROCK1 29/4885KDM1A 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.